Simpson Thacher represented The Carlyle Group (Carlyle) in connection with the formation and closing of Abingworth’s new Clinical Co-Development Co-Investment Fund (CCD-CIF) at $356 million. Abingworth, a leading international life sciences investment group, is a part of Carlyle. CCD-CIF was significantly oversubscribed, exceeding its target of $300 million.~~Alongside the Abingworth Clinical Co-Development Fund 2 (ACCD 2), a fund of $583 million, Abingworth has raised over $930 million in new funds since 2021 to invest in the development of late-stage clinical programs from pharmaceutical and biotechnology companies in the U.S., U.K., Europe and Asia-Pacific, developing innovative therapeutics with potential to significantly improve human health.~~The Simpson Thacher team included David Greene, Lina Zhou, Yoonji Woo, Bradley Benson, Jessica Shieh, Joseph Teitelbaum, In Young Kim and Nikaury Payano (Private Funds); and Nancy Mehlman, Jodi Schneider and Lina Pan (Tax).